Is Sonoma Pharmaceuticals, Inc. (SNOA) Halal?

NASDAQ Healthcare United States $4M
✗ NOT HALAL
Confidence: 90/100
Sonoma Pharmaceuticals, Inc. (SNOA) is Not Halal under AAOIFI Standard 21. While the debt ratio of 7.4% is acceptable, the cash and interest-bearing securities ratio of 130.5% exceeds the 30% threshold. Sonoma Pharmaceuticals, Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from March 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 7.4%
/ 30%
130.5%
/ 30%
91.4%
/ 30%
5.62%
/ 5%
✗ NOT HALAL
DJIM 7.4%
/ 33%
130.5%
/ 33%
91.4%
/ 33%
5.62%
/ 5%
✗ NOT HALAL
MSCI 2.2%
/ 33%
39.2%
/ 33%
27.5%
/ 33%
5.62%
/ 5%
✗ NOT HALAL
S&P 7.4%
/ 33%
130.5%
/ 33%
91.4%
/ 33%
5.62%
/ 5%
✗ NOT HALAL
FTSE 2.2%
/ 33%
39.2%
/ 33%
27.5%
/ 50%
5.62%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-1.95
P/B Ratio
1.1
EV/EBITDA
-0.7
EV: $2M
Revenue
$14M
Growth: 22.0%
Beta
1.7
High volatility
Current Ratio
2.9

Profitability

Gross Margin 38.2%
Operating Margin -15.6%
Net Margin -19.0%
Return on Equity (ROE) -81.2%
Return on Assets (ROA) -12.7%

Cash Flow & Balance Sheet

Operating Cash Flow-$88,000
Free Cash Flow-$168,000
Total Debt$305,000
Debt-to-Equity19.1
Current Ratio2.9
Total Assets$14M

Price & Trading

Last Close$2.10
50-Day MA$2.84
200-Day MA$3.50
Avg Volume16K
Beta1.7
52-Week Range
$1.75
$6.92

About Sonoma Pharmaceuticals, Inc. (SNOA)

CEO
Ms. Amy M. Trombly Esq., J.D.
Employees
8
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Exchange
NASDAQ
Market Cap
$4M
Currency
USD

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Sonoma Pharmaceuticals, Inc. (SNOA) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Sonoma Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Sonoma Pharmaceuticals, Inc.'s debt ratio?

Sonoma Pharmaceuticals, Inc.'s debt ratio is 7.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.2%.

What are Sonoma Pharmaceuticals, Inc.'s key financial metrics?

Sonoma Pharmaceuticals, Inc. has a market capitalization of $4M, and revenue of $14M. The company maintains a gross margin of 38.2% and a net margin of -19.0%. Return on equity stands at -81.2%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.